Fast Five Quiz: Antibiotic Best Practices

Mary L. Windle, PharmD


September 11, 2019

ASCO/IDSA guideline recommendations for antibiotic use in patients with neutropenic cancer include the following:

  • Monotherapy with an antipseudomonal beta-lactam agent, such as cefepime, a carbapenem (eg, meropenem or imipenem-cilastatin), or piperacillin-tazobactam is recommended.

  • Other antimicrobials (eg, aminoglycosides, fluoroquinolones, vancomycin) may be added for management of complications (eg, hypotension, pneumonia) or if antimicrobial resistance is suspected or proven.

  • Vancomycin or other agents active against aerobic gram-positive cocci are not recommended as a standard part of the initial antibiotic regimen for fever and neutropenia; such agents should be considered for specific clinical indications, including suspected catheter-related infection, skin or soft-tissue infection, pneumonia, or hemodynamic instability.

According to the ASCO/IDSA guidelines, antibiotic prophylaxis with a fluoroquinolone is recommended for patients who are at high risk for febrile neutropenia or profound, protracted neutropenia (eg, most patients with acute myeloid leukemia/myelodysplastic syndromes or hematopoietic stem-cell transplantation treated with myeloablative conditioning regimens). Antibiotic prophylaxis is not routinely recommended for patients with solid tumors.

Read more about the ASCO/IDSA guidelines.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: